PANDAS

Doctors for Disaster Preparedness (DDP) Invites Participation in Medical News Discussion

Retrieved on: 
Lunedì, Marzo 27, 2023
Death, Vitamin A deficiency, Obesity, Health, Physician, Patient, COVID, Safety, Person, DDP, Pharmaceutical industry, PANDAS

Additionally, many medical society meetings were cancelled or became virtual because of COVID and have not resumed.

Key Points: 
  • Additionally, many medical society meetings were cancelled or became virtual because of COVID and have not resumed.
  • The Tucson Medical News Discussion Group , comprised of physicians and nonphysicians who were members of a society's public health committee until it was disbanded, continues to meet to discuss health-related issues of general interest.
  • The group is now posting summaries and inviting participation, states Doctors for Disaster Preparedness (DDP) president Jane M. Orient, M.D.
  • Doctors for Disaster Preparedness provides information to help save lives in the event of natural or man-made disasters.

Octapharma USA Grant Supports PANS/PANDAS Education Event at NHIA Conference March 27 in Washington, D.C.

Retrieved on: 
Giovedì, Marzo 23, 2023
University of Arizona College of Medicine – Tucson, PANS, Janet Woodcock, Sodium chloride, Medical Affairs Bureau, University, Erythema ab igne, Octapharma, Encephalitis, DSM-IV codes, University of Arizona College of Pharmacy, Science, Patient, Immune system, Clutch (eggs), Diagnosis, Research, PANDAS, Conference, Strep, Pharmaceutical industry

The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.

Key Points: 
  • The Octapharma educational grant supports the Immunoglobulin National Society (IgNS) breakfast symposium , "PANS/PANDAS in Children: Controversies, Evidence, Research and Treatment Guidelines for Challenging Cases," to be held Monday, March 27th at 7:30 a.m.
  • Rice, M.D., both of the University of Arizona College of Medicine Tucson and investigators leading the Octapharma PANS/PANDAS clinical trial.
  • "Octapharma is looking forward to sharing valuable information on PANS/PANDAS with NHIA attendees," said Octapharma USA President Flemming Nielsen.
  • For more study information, please contact Huub Kreuwel, Ph.D., Octapharma USA, Vice President of Scientific and Medical Affairs, at [email protected] or visit ClinicalTrials.gov (Identifier: NCT04508530).

Bitpanda-backed Pantos Launches Public Beta of Its Multichain Token System

Retrieved on: 
Mercoledì, Febbraio 22, 2023
Ethereum, Avalanche, EVM, University, Polygon, RBI, Internet, PANDAS, PAN, Maintenance, Entrepreneurship, Blockchain, Research, Raiffeisen Bank International, Partnership, BNB, N26, TU Wien, Cryptocurrency, Pantos, Bitpanda, Fantom

Pantos, a multichain token system conceived by the team behind Bitpanda, announces the public beta launch of its multichain protocol today.

Key Points: 
  • Pantos, a multichain token system conceived by the team behind Bitpanda, announces the public beta launch of its multichain protocol today.
  • Pantos is introducing a new Multichain Token Standard called PANDAS (Pantos Digital Asset Standard) to bring a truly multichain token system to the masses, enabling secure and seamless Web3 interoperability.
  • Pantos aims to improve this by offering a reliable infrastructure and the right tools to empower developers to easily create multichain assets.
  • Bitpanda will also be one of the first adopters of Pantos’ multichain token system.

New Research Shows Rare Gene Variants Can Impact Neuropsychiatric Disorders Triggered By Strep And Other Infections

Retrieved on: 
Venerdì, Ottobre 7, 2022
Physician, Lists of diseases, PANDAS, Infection, Parent, Patient, Lyme disease, Treating, MD, DRS, Strep, Doctor of Philosophy, Pediatrics, Awareness, Bacteria, Brain, Anxiety, Autism, Tic, Gene, OCD, Pharmaceutical industry, Vaccine, PANS, Streptococcus

PORTSMOUTH, N.H., Oct. 7, 2022 /PRNewswire-PRWeb/ -- Researchers from the US and the Netherlands released new findings at a symposium in Portsmouth, New Hampshire that could impact future testing for post-infectious neuropsychiatric disorders called PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)

Key Points: 
  • Says Lachman, "These problems create PANS skepticism among physicians, preventing PANS patients from getting proper care.
  • One way to address this conundrum is to identify genes that might be involved in the predisposition to develop PANS."
  • In addition, overlap was found between the mutations that increase PANS susceptibility with autism spectrum disorders and immune disorders.
  • The team released their findings at the symposium, entitled PANDAS/PANS: Recognizing, Understanding and Treating Immune-Mediated Neuropsychiatric Disorders in Portsmouth, New Hampshire last week.

Health Professionals Urged To Attend NH Symposium On The Latest Breakthroughs For Neuropsychiatric Disorders Triggered By Strep And Other Infections

Retrieved on: 
Giovedì, Settembre 15, 2022
Union Church (Portsmouth, Rhode Island), Dartmouth–Hitchcock Medical Center, Inflammation, Infection, Cytokine, Strep, Nursing, Brain, Mycoplasma, Biomarker, Hospital, Immunology, Massachusetts General Hospital, Genetics, Physician, OCD, Tic, Treating, Disorder, Neuropsychiatry, Anxiety, Doctor of Philosophy, Science, Pediatrics, Insurance, Research, Parent, Awareness, Multimedia, Immune system, PANDAS, Education, View, Medicine, Pharmaceutical industry, Streptococcus

PORTSMOUTH, N.H., Sept. 15, 2022 /PRNewswire/ -- Rapid onset of OCD, anxiety, and tics in children and young adults can be triggered by a strep (streptococcal) infection, however, the underlying cause is not widely recognized or treated, according to researchers and physicians who specialize in post-infectious neuropsychiatric disorders called PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome).

Key Points: 
  • The symposium, entitled PANDAS/PANS: Recognizing, Understanding and Treating Immune-Mediated Neuropsychiatric Disorders, will share new advances and provide an opportunity for clinicians to discuss improving early detection and treatment.
  • To register visit https://thealexmanfullfund.org/symposium/
    Attendance is limited to physicians, psychologists, nurses, mental health professionals, researchers, policymakers, and others involved in the treatment, education, research, or funding related to such disorders.
  • In addition, the latest research on the role of genetics, the microbiome, and cytokines will also be presented.
  • Ongoing research is bringing us closer to achieving our goal of quickly identifying post infectious neuropsychiatric illnesses and finding a cure."

Moleculera Labs and General Genomics Form Strategic Alliance to Utilize Proprietary AI to Provide Personalized Medicine for Autoimmune Neuropsychiatric Disorders

Retrieved on: 
Martedì, Luglio 26, 2022
Patient, Algorithm, CLIA, Knowledge, Brain, University, Anxiety, ASD, Intelligence, Physician, Pediatrics, Autoantibody, Doctor of Philosophy, PANDAS, Psychiatry, CEO, Research, Degenerative disease, University of Oklahoma Health Sciences Center, Phobia, Lists of diseases, Probability, Artificial intelligence, GGI, Medicine, Risk, Plasma protein binding, COLA, ADD/ADHD, Rapid eye movement sleep behavior disorder, Dysthymia, GE, General Electric, Central nervous system, MBA, Disease, Genomics, Precision medicine, Autism, Depression, Biology, Entrepreneurship, Engineering, Tic disorder, Infection, AI, Basal ganglia, Medical device, Pharmaceutical industry

OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.

Key Points: 
  • OKLAHOMA CITY, July 26, 2022 /PRNewswire/ -- Moleculera Labs, Inc. (Moleculera) and General Genomics, Inc. (GGI) announce the formation of a strategic alliance between the two companies.
  • Moleculera Labs, Inc. is a precision medicine company focused on identifying the underlying root of neurologic, psychiatric, and behavioral disorders.
  • General Genomics, Inc. is a cutting-edge bioinformatics, AI and machine learning organization founded by former General Electric (GE) and Baker Hughes AI engineers.
  • Moleculera Labs is a precision medicine company focused on understanding the biological roots and testing for autoimmune neuropsychiatric disorders.

Protenus Relaunches Website Aimed at Continuous Innovation and Support of Healthcare Compliance

Retrieved on: 
Martedì, Giugno 7, 2022
Privacy, PANDAS, The Last Best Place, Modern Healthcare, Organization, Solution, Chief, The Baltimore Sun, GLOBE, Patient, American, Risk, Forbes, American City Business Journals, Heart, Health insurance, Pharmaceutical industry, Health care

BALTIMORE, June 07, 2022 (GLOBE NEWSWIRE) -- Protenus, the leading healthcare compliance analytics platform empowering healthcare to eliminate risk, announces today the launch of its updated website, www.protenus.com .

Key Points: 
  • BALTIMORE, June 07, 2022 (GLOBE NEWSWIRE) -- Protenus, the leading healthcare compliance analytics platform empowering healthcare to eliminate risk, announces today the launch of its updated website, www.protenus.com .
  • "We are excited to announce the launch of our newly designed website, offering a better user experience with easier navigation and relevant content that also demonstrates our experience and commitment to healthcare compliance analytics and risk elimination for healthcare organizations nationwide," remarked Michelle Del Guercio, Chief Marketing Officer of Protenus.
  • As a leading healthcare compliance analytics AI provider, Protenus created the new website to showcase services, solutions, and industry information in a format that enables site visitors to find their desired content quickly.
  • We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients.

What's Wrong Wellness: One Mother's Chilling Medical Discovery That Could Be Impacting Many Families

Retrieved on: 
Giovedì, Settembre 30, 2021
Language, Hope, Interview, Parent, Morgan James Publishing, PANDAS, Patient, Disorder, Book, Child, Family, Disease, Science, Disturbance, Morgan James, Conditional sentence, Time, Obsessive–compulsive disorder, GLOBE, Toy, Pharmaceutical industry

When Elizabeth Harris' son suddenly began exhibiting signs of Obsessive-Compulsive Disorder and other strange behaviors, she was determined to get to the bottom of the cause.

Key Points: 
  • When Elizabeth Harris' son suddenly began exhibiting signs of Obsessive-Compulsive Disorder and other strange behaviors, she was determined to get to the bottom of the cause.
  • This mother of four spends much of her time educating medical professionals and other parents on her discoveries.
  • She resides in Franklin, Tennessee, where she owns What's Wrong Wellness which provides alternative options forchildren in need.You can Pre-Order now from www.whatswrongwellness.com/pre-order .
  • What's Wrong With My Child9781631954979has 252 pages and is being sold as a trade paperback for $17.95.